The study findings add evidence to support cannabidiol’s effectiveness in reducing severe seizures in this patient population.
Top news of the day from across the health care landscape.
Investigative migraine therapy galcanezumab has reported more statistically significant benefits across multiple relevant outcomes.
Tofacitinib is the first and only Janus kinase inhibitor approved by the FDA for this patient population.
In response to the increasing incidence of colorectal cancer in young and middle-aged individuals, the American Cancer Society has updated its screening recommendations.
The addition of nelarabine (Arranon) to standard chemotherapy provided further benefit for patients with moderate or high risk of disease recurrence.
The results of a recent study provide important insights into what might influence the development of multiple sclerosis.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.